CLLS

Companies
NASDAQ
Cellectis S.A. - ADR
Health Care
Price Chart
Overview

About CLLS

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Market Cap
$257.2M
Volume
60.8K
Avg. Volume
104.1K
P/E Ratio
-2.0789475
Dividend Yield
0.00%
Employees
249.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
2.23
High Correlation
Volatility
High (0.85)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for CLLS.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, CLLS shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$257.2M
Volume60.8K
P/E Ratio-2.08
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 26, 2025

PortfolioPilot Analysis

Get AI-powered insights on how CLLS fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025